Pfizer fails with AstraZeneca offer, LinkedIn loses $13.3M, Facebook/Oculus deal under fire

Here are some of the stocks the Yahoo Finance team is keeping an eye on today:

The first is Pfizer (PFE) after AstraZeneca (AZN) rejected a second takeover bid that would have created the world's largest pharmaceutical company. U.S.-based Pfizer made a bid that valued British AstraZeneca at just over $106 billion. AstraZeneca said it had "no hesitation" rejecting the offer it believed "substantially" undervalued the company. Pfizer made a $100 billion bid for the company in January.

We're also watching LinkedIn (LNKD). The social network for business professionals reported a loss yesterday of $13.3 million despite a 46% rise in revenue to about $473 million. They attributed net the loss, which analysts were expecting, to expansion in China and the acquisition of Bright which connects people to employers. The company also reported membership increased 7% to 296 million.

And we're watching Facebook (FB) after reports suggesting there could be a little snag in Zuckerberg and company's $2 billion deal to acquire virtual reality darling Oculus Rift. A company called ZeniMax Media is claiming that their former employee, and current Oculus Chief Technology Officer John Carmack, shared proprietary information with Oculus before and after he joined the company last summer. ZeniMax says that information was key to Oculus' rocket-like ascent into the technology elite. Oculus said it will defend itself against the allegations. Carmack hasn't responded publicly.